Related Experiment Video
Updated: Apr 27, 2026

Colorectal Cancer Cell Surface Protein Profiling Using an Antibody Microarray and Fluorescence Multiplexing
Published on: September 25, 2011
[Diagnostic capability of carcinoembryonic antigen elevation]
Antonio Cerezo Ruiz1, Francisco Rosa Jiménez2, José Antonio Lobón Hernández3
1Aparato Digestivo. Hospital Alta Resolución Alcaudete, Agencia Sanitaria Alto Guadalquivir, Consejería de Salud y Bienestar Social, Junta de Andalucía.
A small percentage of patients with mild carcinoembryonic antigen (CEA) elevation are diagnosed with cancer. Investigating these cases incurs significant direct and indirect costs.
Area of Science:
- Oncology
- Clinical Diagnostics
Background:
- Limited data exists on the diagnostic accuracy of carcinoembryonic antigen (CEA) levels exceeding three times the normal range.
- Understanding cancer prevalence in patients with mild CEA elevation is crucial for diagnostic strategies.
Purpose of the Study:
- To determine the prevalence of underlying cancer in patients with mild CEA elevation (3-10 ng/ml).
- To assess the mean cost associated with CEA determination in this patient group.
Main Methods:
- Retrospective analysis of 100 patients with CEA elevation (3-10 ng/ml) and suspected cancer from 2001-2007.
- Inclusion criteria: referral to gastroenterology or internal medicine outpatient units.
Main Results:
- Cancer was diagnosed in 7% of patients (gastric, lung, colon).
- No significant difference in baseline CEA levels was observed between cancer and non-cancer groups (p=0.2).
- The mean cost per patient for CEA determination was approximately 504 €.
Conclusions:
- Mild CEA elevation (3-10 ng/ml) is associated with a low prevalence of underlying malignancy.
- Diagnostic workup for these patients represents a considerable financial cost.
More Related Videos
08:28Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
Published on: May 9, 2025
07:33Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy
Published on: September 19, 2025